3651 results for «211»
3651 results
Controversies and conversations in TAVI
21 May 2026 – From EuroPCR 2026
This session addresses key controversies and discussions in transcatheter aortic valve implantation (TAVI), including the role of invasive coronary angiography prior to TAVI, use of cangrelor during combined TAVI and high-risk PCI, and discrepancies in aortic valve stenosis assessment methods. Additional topics cover operator models, valve...
Combination of dedicated devices for optimal treatment of calcified lesions
20 May 2026 – From EuroPCR 2026
Focused on the optimal treatment of heavily calcified coronary lesions, this session presents a comprehensive overview of dedicated device combinations. It highlights strategies such as rotablation, rotatripsy, and approaches to managing protruding calcified nodules and undilatable lesions, emphasizing a stepwise approach to complex calcium modification in...
PCI in cardiogenic shock - Possibilities and limitations
20 May 2026 – From EuroPCR 2026
This session evaluates percutaneous coronary intervention (PCI) in the context of cardiogenic shock, discussing both possibilities and limitations. It features complex cases including Impella-supported rotablation in elderly patients, microaxial flow pump use, and challenging interventions in young patients with multivessel chronic total occlusions, providing insights into...
Imaging guided ultralow contrast PCI
20 May 2026 – From EuroPCR 2026
This session focuses on imaging-guided ultralow contrast PCI techniques designed to minimize contrast-induced nephropathy risk. It includes IVUS-guided strategies for distal left main bifurcation PCI, zero-contrast interventions in renal transplant patients, and precision stent placement without contrast use, emphasizing safety, precision, and frugality in contemporary PCI...
A series of complex real-word challenges STEMI treatment from very different countries
21 May 2026 – From EuroPCR 2026
This session showcases a series of complex STEMI treatment challenges from diverse international settings, highlighting difficult coronary anatomies and complicated procedures. It discusses nuanced clinical scenarios where artery recanalisation does not always equate to reperfusion, and presents stepwise approaches to managing multivessel disease, renal failure, and...
Mitral valve-in-valve, valve-in-ring, valve replacement: procedure challenges
20 May 2026 – From EuroPCR 2026
This session addresses procedural challenges in mitral valve interventions, including valve-in-valve, valve-in-ring, and valve replacement techniques. It covers lifetime management of patients with atrial fixated transcatheter mitral valve replacement (TMVR), approaches to recurrent mitral regurgitation, complex valve-in-valve cases, and hybrid strategies for valve-in-ring implantation, highlighting innovative...
Bifurcation and heavily calcified lesions
21 May 2026 – From EuroPCR 2026
This session addresses the evaluation and treatment of bifurcation and heavily calcified coronary lesions. It includes case-based discussions on complex left main PCI and the use of drug-coated balloons (DCB) for bifurcation lesions and in-stent restenosis, providing evidence-based approaches to optimize outcomes in these challenging lesion...
Intracoronary imaging guidance in challenging PCI scenarios
20 May 2026 – From EuroPCR 2026
This session highlights the critical role of intracoronary imaging, particularly IVUS, in guiding complex percutaneous coronary interventions. It presents techniques such as IVUS-guided puncture of neo-ostia, stent implantation for ostial lesions, and innovative procedural methods like the Heart POTTER technique, underscoring the importance of precise imaging...
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024